Skip to main
IMUX
IMUX logo

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc is advancing its clinical-stage pipeline with promising early-stage results for its candidate IMU-856, which has demonstrated a statistically significant increase in GLP-1 levels in celiac disease patients, positioning it for potential broader applications in chronic inflammation and metabolic benefits. The findings suggest potential for strategic partnerships and further financing opportunities that may enhance the company's financial standing and growth prospects as the drug transitions toward Phase 2 development. Additionally, the promising preclinical data indicating weight management effects further supports a positive outlook on the effectiveness and market potential of Immunic's innovative therapies.

Bears say

The negative outlook on Immunic Inc.'s stock stems from significant risks related to their product development and financial stability. Key concerns include the potential failure of their developmental candidates to meet market revenue expectations due to limited market size, penetration rates, and pricing strategies. Additionally, the company faces challenges in securing necessary capital to sustain operations and advance their clinical programs, which could hinder their commercialization efforts.

Immunic Inc (IMUX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Buy based on their latest research and market trends.

According to 13 analysts, Immunic Inc (IMUX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.